Germ Cell Tumor | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Conferences Trial results

16 September 2024

ESMO 2024 – Torl challenges BioNTech in Claudin6

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Subscribe to Germ Cell Tumor